Naveruclif

<p>Naveruclif is used to treat the following cancers in adults:</p><ul><li>metastatic breast cancer, when the first treatment has stopped working and standard treatment including an anthracycline (another type of cancer medicine) is not suitable. ‘Metastatic’ means that the cancer has spread to other parts of the body;</li><li>metastatic adenocarcinoma of the pancreas, as a first treatment in combination with another cancer medicine, gemcitabine;</li><li>non-small cell lung cancer, as a first treatment in combination with the cancer medicine carboplatin, when the patient cannot have surgery or radiotherapy.</li></ul><p>Naveruclif is a ‘generic medicine’. This means that Naveruclif contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU. The reference medicine for Naveruclif is Abraxane. For more information on generic medicines, see the question-and-answer document here.</p><p>Naveruclif contains the active substance paclitaxel attached to a human protein called albumin.</p>